Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy.
Ritsuzo KozukaMasaru EnomotoYoshimi Yukawa-MutoNaoshi OdagiriKohei KotaniHiroyuki MotoyamaEtsushi KawamuraAtsushi HagiharaHideki FujiiSawako Uchida-KobayashiNorifumi KawadaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2024)
Our findings suggest that a combination of on-treatment HBsAgGi and HBsAg predicts the development of HCC during NA therapy.